Kukje Pharma Co., Ltd.

002720KOSPIPharmaceuticals

Kukje Pharma Co., Ltd. (002720, KOSPI) reported KRW 175bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2023135-2-816385Consolidated
20241567516690Consolidated
20251756618298Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-1.5%-6.2%52%-9.9%
20244.3%3.3%54.1%5.8%
20253.5%3.3%53.6%5.8%

Revenue moved 29.6% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 70bn
Close priceKRW 3,325
Listed shares21,159,832
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)272
Women113 (41.5%)
Average tenure12.4 years
Annual pay, menKRW 81,000,000
Annual pay, womenKRW 51,000,000
Pay ratio, women to men63%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →